PMC10273878_01
Depicted are the serum creatinine courses of the C1q-DSA-positive ABMR cases. "Treatment" refers to combined DFPP + IA treatments; "Sigma" depicts total number of treatments in the respective treatment cycle. The arrows indicate allograft biopsies taken at respective days after transplantation.
bpu-0052-0428-g01.jpg
PMC10273878_04_bpu-0052-0428-g01.jpg
F1
DSA, and at day 1,152, we prompted DFPP + IA (Fig. 1d). Despite significant reduction in C1q-binding DSA Cw4 after treatment with DFPP + IA, the C1q-binding DSA DQB1*06:03 persisted after the whole cycle (Table 4 "late 2").
PMC10273878_02
Depicted are the serum creatinine courses of the C1q-DSA-positive ABMR cases. "Treatment" refers to combined DFPP + IA treatments; "Sigma" depicts total number of treatments in the respective treatment cycle. The arrows indicate allograft biopsies taken at respective days after transplantation.
bpu-0052-0428-g01.jpg
PMC10273878_04_bpu-0052-0428-g01.jpg
F1
DSA, and at day 1,152, we prompted DFPP + IA (Fig. 1d). Despite significant reduction in C1q-binding DSA Cw4 after treatment with DFPP + IA, the C1q-binding DSA DQB1*06:03 persisted after the whole cycle (Table 4 "late 2").
PMC10273878_03
Depicted are the serum creatinine courses of the C1q-DSA-positive ABMR cases. "Treatment" refers to combined DFPP + IA treatments; "Sigma" depicts total number of treatments in the respective treatment cycle. The arrows indicate allograft biopsies taken at respective days after transplantation.
bpu-0052-0428-g01.jpg
PMC10273878_04_bpu-0052-0428-g01.jpg
F1
DSA, and at day 1,152, we prompted DFPP + IA (Fig. 1d). Despite significant reduction in C1q-binding DSA Cw4 after treatment with DFPP + IA, the C1q-binding DSA DQB1*06:03 persisted after the whole cycle (Table 4 "late 2").
PMC10273878_04
Depicted are the serum creatinine courses of the C1q-DSA-positive ABMR cases. "Treatment" refers to combined DFPP + IA treatments; "Sigma" depicts total number of treatments in the respective treatment cycle. The arrows indicate allograft biopsies taken at respective days after transplantation.
bpu-0052-0428-g01.jpg
PMC10273878_04_bpu-0052-0428-g01.jpg
F1
DSA, and at day 1,152, we prompted DFPP + IA (Fig. 1d). Despite significant reduction in C1q-binding DSA Cw4 after treatment with DFPP + IA, the C1q-binding DSA DQB1*06:03 persisted after the whole cycle (Table 4 "late 2").
a Depicted are the absolute alterations of the respective molecules before and after a single DFPP + IA treatment. Index measurements ("before") are normalized to 100%. b Total serum C1q levels before and after DFPP + IA treatments on seven consecutive treatment days. These data derive from patients "early 1" and "late 1." The dashed lines mark the lower and upper border of normal C1q values. All data are presented as median + IQR. *** p < 0.001; **** p < 0.0001.
bpu-0052-0428-g02.jpg
PMC10273878_04_bpu-0052-0428-g02.jpg
F2
DFPP + IA proved effective in reducing macromolecular proteins as measured before and after treatment (Fig. 2a). However, in a series of consecutive daily treatments, we did not find a sustained reduction in plasmatic C1q (Fig. 2b, n = 3 data points for every column).